Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes, I was expecting something more material as well. The information was largely already known info and the only additional information was on some further preclinical trials carried out on mice. Still can't figure out why this would warrant a suspension on ASX. Those guys must be scratching their heads as well.
Rscorpio, yes, you are right in your comments. I was just expecting something that warranted a suspension rather than a clinical update. I was probably just a little enthusiastic and expected more.
There was talk of delisting in Aus ? Possibly Linked in anyway ?
The suspension RNS does say "The halt was requested by the Company pending the release of an announcement by the Company in relation to further findings on ArtemiCTM."
And today that is what they have released. Will be surprised if anything further is announced today.
I had the exact same thoughts @Rosewall. Surely that can't be the reason for the suspension?!
Am I missing something here . If all that has been published is a clinical update, is that sufficient for an exchange suspension? Is there more to come?
We've got the official RNS now as well
Touch wood, fingers crossed, I hope so and GLA
"Looks like a very positive RNS so fingers crossed for a rerate here."
It's positive but not definitive. I think we'll see some PI money coming in but I don't think we see II money coming in until the results of the Phase III trials are announced in due course.
That said, today should be a good day overall.
LOL let's see how THE market reacts to that news LOL
These findings support the understanding of the mechanism of action of ArtemiCTM and additional
potential application of the study product. This data will be used in the design of future clinical trials
of the Company in different indications.
Following the successful Phase II clinical trial results (refer ASX release 15 December 2020),
ArtemiCTM demonstrated efficacy in COVID-19 infected patients. Patients in the treatment group
fully clinically recovered within 15 days of follow up. The ArtemiCTM results delivered a full safety
and efficacy profile, demonstrating its ability to improve and expedite the clinical recovery in mild
and moderate COVID-19 patients.
MGC Pharma continues the preclinical development on ArtemiC™ while progressing with the clinical development
program for CimetrATM as an Investigational Medicinal Product (IMP) to demonstrate the full efficacy and
pharmacokinetic profile of the treatment in a Phase III clinical trial (submitted on the clinical drug development program
of IMP version of ArtemiCTM).
Importantly once the inflammation process associated with COVID-19 is under control, the effects of ‘long COVID’, the
post COVID syndrome should be minimised. MGC Pharma will initiate a sub-trial in combination with the upcoming
Phase III clinical trial to prove this hypothesis.
As per the FDA recommendations and based on the last findings, MGC Pharma will initiate a sub-trial for patients who
complete the Phase III trial, observing them for an additional three (3) months to document the post COVID syndrome
symptoms both in the treatment and placebo groups.
Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “The findings from the phase II clinical
trials which are supported by the completed preclinical trial results, continue to demonstrate the effectiveness of
ArtemiC™ in treating patients with different variants of COVID-19.
“We are now looking to get ArtemiCTM into more territories as a supplement and herbal health product following these
findings.”
Looks like a very positive RNS so fingers crossed for a rerate here.
Key Highlights:
• ArtemiCTM Rescue (ArtemiC™) designed with the scientific aim to target viral infections
with inflammatory complications, and was successfully evaluated on COVID-19 infected
patients in a double-blind, placebo-controlled Phase II clinical trial.
• Preclinical and Clinical results to date have demonstrated ArtemiCTM‘s mechanism of
action as an anti-inflammatory and immunomodulatory agent effective in the prevention
of increased cytokine production, found in different variants and mutations of COVID-19;
the forerunner of cytokine storm – believed to be the main reason for mortality in severe
COVID-19 patients.
• Preclinical trial work, completed by MGC Pharma, showed the ability of ArtemiCTM to
decrease the markers of inflammation (IFN-g, IL-1a and TNF-a), in the bronchoalveolar
lavage fluid (BALF) of mice in the animal model of cytokine storm related to COVID-19
and in human trials to control the inflammation process in COVID-19 patients.
• Successful ArtemiCTM Phase II clinical trials performed in India and Israel have
demonstrated the capacity of ArtemiCTM to improve and expedite the clinical recovery in
mild to moderate patients suffering from COVID-19.
MGC Pharmaceuticals Ltd (ASX, LSE: MXC, ‘MGC Pharma’ or ‘the Company’), a European based
bio-pharma company specialising in the production and development of phytocannabinoid-
derived medicines, is pleased to announce further results from the Phase II clinical and preclinical
studies on ArtemiCTM, evaluating the efficacy on anti-inflammatory agents for increased cytokine,
which is found in different variants and mutations of COVID-19 and post COVID-19 syndrome.
The mechanism of action of ArtemiCTM is focused on the anti-inflammatory effect and prevention
of cytokine storm – believed to be the main reason for mortality in COVID-19 patients. Preclinical
and clinical results to date support ArtemiCTM being effective for addressing cytokine over
production in all tested COVID patients. On 15 December 2020, the Company released to the ASX
results from its Phase II clinical trial results from patients in India and Israel.
The preclinical trial “Evaluation the Efficacy of ArtemicTM Treatment in ARDS Model in Mice” was
performed in the SIA preclinical Lab (GLP certified) in Israel.
The ARDC model is the recommended preclinical animal model for the cytokine storm for the
prediction of the human model of COVID-19 patients. The level of the pro-inflammatory markers
was measured in blood and BALF (bronchoalveolar lavage fluid) of the mice going through the
cytokine storm. The results demonstrated decreased blood and BALF cytokine levels in the study
arm treated by ArtemicTM. Refer to Annexure A for additional information on the preclinical study
and summary of results.
These findings support the understanding of the mechanism of action of ArtemiCTM and additional
potential application of the study product. This data will be used in t
We were at 8.95 less than 3 months ago, if we can get back to that price I will be happy.
I tried pasting the link to the PDF but it wouldn't have it
Scroll down
https://www2.asx.com.au/markets/company/mxc